ORGANIC CATION TRANSPORTERS - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 30

28. Nagel G, Volk C, Friedrich T, Ulzheimer JC, Bamberg E, Koepsell H. 1997. A reevaluation
of substrate specificity of the rat cation transporter rOCT1. J Biol Chem 272(51):31953-
31956.
29. Sweet DH, Pritchard JB. 1999. rOCT2 is a basolateral potential-driven carrier, not an
organic cation/proton exchanger. Am J Physiol 277(6 Pt 2):F890-F898.
30. Fujita T, Urban TJ, Leabman MK, Fujita K, Giacomini KM. 2006. Transport of drugs in
the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm
Sci 95(1):25-36.
31. Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C, Arndt P, Ulzheimer
JC, Sonders MS, Baumann C, et al. 1998. Human neurons express the polyspecific cation
transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and
memantine. Mol Pharmacol 54(2):342-352.
32. Jonker JW, Schinkel AH. 2004. Pharmacological and physiological functions of the
polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp
Ther 308(1):2-9.
33. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. 2005. Metformin
is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1.
Drug Metab Pharmacokinet 20(5):379-386.
34. Bourdet DL, Pritchard JB, Thakker DR. 2005. Differential substrate and inhibitory ac-
tivities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1;
SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther 315(3):
1288-1297.
35. Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor
T, Clark AG, Herskowitz I, Giacomini KM. 2002. Polymorphisms in a human kidney
xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 12(5):395-405.
36. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E. 1999. Selective substrates for
non-neuronal monoamine transporters. Mol Pharmacol 56(1):1-10.
37. Hayer-Zillgen M, Bruss M, Bonisch H. 2002. Expression and pharmacological profile
of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol
136(6):829-836.
38. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH,
Sekine T, Endou H. 2002. Human organic anion transporters and human organic cation
transporters mediate renal antiviral transport. J Pharmacol Exp Ther 300(3):918-924.
39. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V.
1998. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine
transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol
Chem 273(49):32776-32786.
40. Eisenhofer G. 2001. The role of neuronal and extraneuronal plasma membrane transporters
in the inactivation of peripheral catecholamines. Pharmacol Ther 91(1):35-62.
41. Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H. 2002. Human or-
ganic anion transporters and human organic cation transporters mediate renal transport of
prostaglandins. J Pharmacol Exp Ther 301(1):293-298.
42. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K. 2002. cDNA cloning, functional
characterization, and tissue distribution of an alternatively spliced variant of organic cation
transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol
13(7):1703-1710.